-

06:31:43 PM

ACER Stock News

ACER - Acer Therapeutics Inc

01/09/23 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet

RHEA-AI

neutral

01/05/23 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on

RHEA-AI

neutral

12/29/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The

RHEA-AI

neutral

12/27/22 8:30 AM

Nasdaq : ACER

fda approvallow float

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”)

RHEA-AI

positive

11/30/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Announces $1.5M Private Placement

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it

RHEA-AI

neutral

11/14/22 5:08 PM

Nasdaq : ACER

earningslow float

Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported

RHEA-AI

neutral

10/26/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition,

RHEA-AI

positive

10/06/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder

$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate the potential for ACER-801 to reduce the frequency and severity of acute stress disorder and

RHEA-AI

negative

10/05/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a distinct group of brain cells in a region of the brain that controls the formation and

RHEA-AI

negative

10/03/22 8:30 AM

Nasdaq : ACER

low float

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ACER Data

IndustryPharmaceutical Preparation Manufacturing
Websiteacertx.com
CeoChristopher Schelling
Security nameAcer Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressOne Gateway Center (300 Washington St.)
Address2Suite 351
StateMassachusetts
CityNewton
Zip02458
CountryUS
Phone18449026100

About Acer Therapeutics Inc

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); emetine hydrochloride, a host-directed therapy against a variety of infectious diseases, initially for the treatment of patients with COVID-19; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer's product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.